Independent genetic signals from the cross-ancestry meta-analysis were searched in OpenTargets.org37 for druggability and medication target status based on their nearest genes. Among them, OPRM1 implicated naltrexone and GABRA4 may implicate acamprosate, both current treatments for AUD. Additionally, DRD2, CACNA1C, DPYD, PDE4B, KLB, BRD3, NCAM1, FTO and MAPT were identified as druggable genes.
